NCT05745623

Study of ICP-723 in Patients With Advanced Solid Tumors or Primary Central Nervous System Tumors

A Multi-center, Non-Randomized, Open-Label Phase 2 Basket Clinical Trial to Evaluate ICP-723 in Patients With Advanced Solid Tumors or Primary Central Nervous System Tumors

• Status: Recruiting
• Phase: Phase 1 / Phase 2
• Study type: Interventional
• Enrollment: 70 (estimated)
• Sponsor: Beijing InnoCare Pharma Tech Co., Ltd. · Industry
• Sex: All
• Age: 2 Years
• Healthy volunteers: Not accepted

Summary

A Multi-center, Non-Randomized, Open-Label Phase 2 Basket Clinical Trial to Evaluate ICP-723 in Patients with Advanced Solid Tumors or Primary Central Nervous System Tumors

Conditions

• Advanced Solid Tumors Harboring NTRK Fusion
• Primary Central Nervous System Tumors Harboring NTRK Fusion

Interventions

Type	Name	Description
DRUG	ICP-723	ICP-723 tablet administered orally，once a day，for every 28 days as one cycle

Timeline

• Start date: 2022-12-27
• Primary completion: 2027-12-25
• Completion: 2028-12-25
• First posted: 2023-02-27
• Last updated: 2025-09-11

Locations

1 site across 1 country: China